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Introduction
Progressive multifocal leukoencephalopathy (PML) is an oppor- Maintenance Chemotherapy in Acute Promyelocytic Leukemia: The Thin Line Between Survival and Immunosuppression 02 diagnosis, the interruption of the causing agent and a rapid restoration of the baseline immune function could lead to survival, and quasi-complete recovery is possible. We report a case describing the dilemma between the wish to consolidate optimally the recovery, and the risks related to this approach.
Case Report
A 54 year-old woman with high risk PML-RARA positive acute promyelocytic leukemia (APL) in hematologic and molecular remission for two years presented with progressive myoclonus and right leg weakness. She had previously received remission induction chemotherapy with tretinoin (ATRA), daunorubicin, cytarabine, and consolidation cycles with ATRA and high dose cytarabine, 
Discussion
PML results from an infection of the oligodendrocytes by JC virus, within the subcortical white matter, often lethal or resulting in permanent neurologic deficits. JC virus is acquired during childhood or young adulthood with a prevalence of 50-70%1. Immunosuppression is a key feature leading to viral reactivation from an extra-neural primary site, involvement of the central nervous system and development of neurologic deficits reflecting the brain areas involved [1] . Concomitant HIV infection is the leading risk factor, but lymphoproliferative malignancies and the use of immunosuppressive drugs are all potential triggers of PML reactivation [2, 3] .
JC virus may be negative in the CSF by quantitative PCR in a patient
with PML proven by biopsy. Weber., et al. estimated that the sensitivity JC virus by quantitative PCR was only 75% [4] .
Conclusion
This case demonstrates that profound and clinically significant [6] . PML should be considered in the context of maintenance chemotherapy for APL. Interruption of immunosuppressive drugs may lead to neurological recovery.
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